share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股SEC公告 ·  05/16 05:11
牛牛AI助理已提取核心訊息
180 Life Sciences Corp. has failed to meet the Nasdaq's minimum stockholders' equity requirement and faces potential delisting. The company was previously notified by Nasdaq on November 15, 2023, of its non-compliance with the $2.5 million equity threshold. Despite submitting a compliance plan and being granted an extension until May 13, 2024, 180 Life Sciences was unable to complete the necessary transactions to meet the requirement. Consequently, on May 14, 2024, Nasdaq issued a delisting determination letter to the company. 180 Life Sciences plans to request a hearing with the Nasdaq Hearings Panel in an attempt to present a new compliance plan and delay delisting. Trading of the company's common stock, under the symbol 'ATNF', will continue on Nasdaq pending the hearing's outcome. Additionally, on the...Show More
180 Life Sciences Corp. has failed to meet the Nasdaq's minimum stockholders' equity requirement and faces potential delisting. The company was previously notified by Nasdaq on November 15, 2023, of its non-compliance with the $2.5 million equity threshold. Despite submitting a compliance plan and being granted an extension until May 13, 2024, 180 Life Sciences was unable to complete the necessary transactions to meet the requirement. Consequently, on May 14, 2024, Nasdaq issued a delisting determination letter to the company. 180 Life Sciences plans to request a hearing with the Nasdaq Hearings Panel in an attempt to present a new compliance plan and delay delisting. Trading of the company's common stock, under the symbol 'ATNF', will continue on Nasdaq pending the hearing's outcome. Additionally, on the same day, the company was notified of non-compliance with Nasdaq's audit committee requirements, which mandates at least three independent directors. The company is seeking to address this issue and expects to regain compliance soon. The potential delisting could significantly impact the company's stock and warrant prices and its ability to raise capital.
180 Life Sciences Corp. 未能達到納斯達克的最低股東權益要求，可能面臨退市風險。納斯達克此前曾於2023年11月15日通知該公司，稱其未遵守250萬美元的股權門檻。儘管提交了合規計劃並獲准延期至2024年5月13日，但180 Life Sciences仍無法完成必要的交易以滿足要求。因此，納斯達克於2024年5月14日向該公司發佈了退市決定函。180生命科學計劃要求納斯達克聽證會小組舉行聽證會，試圖提出新的合規計劃並推遲退市。在聽證會得出結果之前，股票代碼爲 “ATNF” 的公司普通股將繼續在納斯達克交易。此外，該公司在同一天被告知不遵守納斯達克審計委員會的要求，該要求要求至少有三名獨立董事。該公司正在尋求解決這個問題，並預計將很快恢復合規。潛在的退市可能會對公司的股票和認股權證價格及其籌集資金的能力產生重大影響。
180 Life Sciences Corp. 未能達到納斯達克的最低股東權益要求，可能面臨退市風險。納斯達克此前曾於2023年11月15日通知該公司，稱其未遵守250萬美元的股權門檻。儘管提交了合規計劃並獲准延期至2024年5月13日，但180 Life Sciences仍無法完成必要的交易以滿足要求。因此，納斯達克於2024年5月14日向該公司發佈了退市決定函。180生命科學計劃要求納斯達克聽證會小組舉行聽證會，試圖提出新的合規計劃並推遲退市。在聽證會得出結果之前，股票代碼爲 “ATNF” 的公司普通股將繼續在納斯達克交易。此外，該公司在同一天被告知不遵守納斯達克審計委員會的要求，該要求要求至少有三名獨立董事。該公司正在尋求解決這個問題，並預計將很快恢復合規。潛在的退市可能會對公司的股票和認股權證價格及其籌集資金的能力產生重大影響。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。